HUP9802431A2 - Pentozán-poliszulfátot tartalmazó, krónikus progresszív érbetegségek kezelésére alkalmas gyógyszerkészítmények - Google Patents

Pentozán-poliszulfátot tartalmazó, krónikus progresszív érbetegségek kezelésére alkalmas gyógyszerkészítmények

Info

Publication number
HUP9802431A2
HUP9802431A2 HU9802431A HUP9802431A HUP9802431A2 HU P9802431 A2 HUP9802431 A2 HU P9802431A2 HU 9802431 A HU9802431 A HU 9802431A HU P9802431 A HUP9802431 A HU P9802431A HU P9802431 A2 HUP9802431 A2 HU P9802431A2
Authority
HU
Hungary
Prior art keywords
treatment
chronic progressive
contg
vascular diseases
pentosan polysulfate
Prior art date
Application number
HU9802431A
Other languages
English (en)
Inventor
Fred P. Sherman
Gary E. Striker
Liliane J. Striker
Original Assignee
Baker Norton Pharmaceuticals, Inc.
The United States Of America, As Represented By The Secretary Department Of Health And Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baker Norton Pharmaceuticals, Inc., The United States Of America, As Represented By The Secretary Department Of Health And Human Services filed Critical Baker Norton Pharmaceuticals, Inc.
Publication of HUP9802431A2 publication Critical patent/HUP9802431A2/hu
Publication of HUP9802431A3 publication Critical patent/HUP9802431A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

A találmány hegesedéssel és/vagy fibrózissal járó krónikűs prőgresszívérrendszeri megbetegedésben (CPVD) szenvedő emlősök kezelésérealkalmas gyógyszerkészítményekre vőnatkőzik, melyek hatóanyagként azérrendszeri betegség kezeléséhez szükséges mennyiségű pentőzán-pőliszűlfátőt vagy ennek gyógyászatilag elfőgadható sójáttartalmazzák. A találmány szerinti készítmények megállítják a CPDV-t,és elősegítik a már kialakűlt hegek és fibrőtikűs sérülésekfelszívódását. ŕ
HU9802431A 1995-06-07 1996-06-03 Pharmaceutical compns. contg. pentosan polysulfate for the treatment of chronic progressive vascular diseases HUP9802431A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/478,347 US5643892A (en) 1995-06-07 1995-06-07 Method of treating chronic progressive vascular diseases
BR9704114-9A BR9704114A (pt) 1995-06-07 1997-07-28 Processo de tratamento de doenças vasculares progressivas crÈnicas

Publications (2)

Publication Number Publication Date
HUP9802431A2 true HUP9802431A2 (hu) 1999-02-01
HUP9802431A3 HUP9802431A3 (en) 2001-06-28

Family

ID=25664870

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9802431A HUP9802431A3 (en) 1995-06-07 1996-06-03 Pharmaceutical compns. contg. pentosan polysulfate for the treatment of chronic progressive vascular diseases

Country Status (14)

Country Link
US (1) US5643892A (hu)
EP (1) EP0809505B1 (hu)
AU (1) AU699012B2 (hu)
BR (1) BR9704114A (hu)
CA (1) CA2210351C (hu)
DE (1) DE809505T1 (hu)
ES (1) ES2115571T3 (hu)
HU (1) HUP9802431A3 (hu)
IL (1) IL121217A (hu)
NO (1) NO313686B1 (hu)
NZ (1) NZ309991A (hu)
TW (1) TW434018B (hu)
WO (1) WO1996040158A1 (hu)
ZA (1) ZA964247B (hu)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010005720A1 (en) * 1995-06-07 2001-06-28 U.S.A. As Represented By The Secretary Department Of Health And Human Services Method of treating chronic progressive vascular scarring diseases
US6255295B1 (en) 1996-12-23 2001-07-03 Nutramax Laboratories, Inc. Aminosugar, glycosaminoglycan or glycosaminoglycan-like compounds, and s-adenosylmethionine composition for the protection, treatment, repair, and reduction of inflammation of connective tissue
UA65587C2 (en) 1997-10-09 2004-04-15 Baker Norton Pharma Method for preventing nephrotoxicity induced by cyclosporins or tacrolimus
DE19747195A1 (de) * 1997-10-24 1999-04-29 Knoll Ag Verwendung von Glykosaminoglykanen zur Herstellung von pharmazeutischen Zubereitungen zur Behandlung von mit Diabetes assoziierten Augenkrankheiten
WO2001052867A1 (en) * 2000-01-19 2001-07-26 The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of pentosan polysulfate to treat certain conditions of the prostate
WO2007014155A2 (en) * 2005-07-22 2007-02-01 Trf Pharma, Inc. Method for treating sickle cell disease and sickle cell disease sequelae
DK2010220T3 (da) * 2006-04-03 2022-05-23 Ceva Animal Health Pty Ltd Stabiliserede pentosanpolysulfat-(pps)-formuleringer
EP2407174B1 (en) 2009-03-11 2014-05-07 Jellice Co., Ltd. Progression inhibitor or prophylactic agent for atherosclerosis, blood cholesterol level-lowering agent, and functional food or food for specified health uses
WO2011088418A2 (en) * 2010-01-15 2011-07-21 Mount Sinai School Of Medicine Inhibition of tnf-alpha induced activation of nfkb by pentosan polysulfate
JP6175431B2 (ja) 2011-06-20 2017-08-02 アイカーン スクール オブ メディシン アット マウント サイナイ ムコ多糖症およびその他のリソソーム障害に対する抗ｔｎｆ療法
US20130273096A1 (en) * 2011-10-05 2013-10-17 Bruce A. Daniels Therapeutic Sulfated Polysaccharides, Compositions Thereof, and Methods for Treating Patients
AU2018437600B2 (en) 2018-08-20 2022-11-17 Reqmed Company, Ltd. Novel pentosan polysulfate sodium preparation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4820693A (en) * 1986-05-22 1989-04-11 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
US4966890A (en) * 1986-04-04 1990-10-30 Angiogenics, Ltd. Method and composition for arresting angiogenesis and capillary, cell or membrane leakage
DE3725554A1 (de) * 1987-08-01 1989-02-09 Hoechst Ag Pharmazeutisches kombinationspraeparat sowie dessen herstellung und verwendung
US5032679A (en) * 1988-12-15 1991-07-16 Glycomed, Inc. Heparin fragments as inhibitors of smooth muscle cell proliferation
EP0466315A3 (en) * 1990-05-30 1992-07-01 Larrian Gillespie Compositions containing xylan sulphates for affecting growth factor function and for inhibiting fibroblast proliferation
US5605938A (en) * 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate

Also Published As

Publication number Publication date
WO1996040158A1 (en) 1996-12-19
EP0809505A4 (en) 1998-07-01
TW434018B (en) 2001-05-16
AU6030096A (en) 1996-12-30
NO313686B1 (no) 2002-11-18
AU699012B2 (en) 1998-11-19
EP0809505A1 (en) 1997-12-03
ES2115571T1 (es) 1998-07-01
ZA964247B (en) 1996-12-04
HUP9802431A3 (en) 2001-06-28
ES2115571T3 (es) 2003-09-01
IL121217A (en) 2000-09-28
NO973081D0 (no) 1997-07-02
BR9704114A (pt) 2000-06-06
NZ309991A (en) 2001-03-30
IL121217A0 (en) 1999-10-28
NO973081L (no) 1997-08-27
EP0809505B1 (en) 2003-04-02
CA2210351A1 (en) 1996-12-19
DE809505T1 (de) 1998-05-28
CA2210351C (en) 2003-09-23
US5643892A (en) 1997-07-01

Similar Documents

Publication Publication Date Title
PT1079806E (pt) Preparacoes para a aplicacao de anti-inflamatorios, especialmente, agentes anti-septicos e/ou agentes de promocao da cura de feridas, no tracto respiratorio superior e/ou no ouvido
ATE349439T1 (de) Neue nicht psychotropische cannabinoide
WO2001001973A8 (en) Highly selective norepinephrine reuptake inhibitors and methods of using the same
TNSN97091A1 (fr) CONJUGUE PEG-IFN α PHYSIOLOGIQUEMENT ACTIF, PROCEDE POUR SA PREPARATION, COMPOSITIONS PHARMACEUTIQUES LE CONTENANT ET LEUR UTILISATION
ES2118834T3 (es) Sistema mejorado de penetracion en la piel para la administracion topica mejorada de farmacos.
HUP9802431A2 (hu) Pentozán-poliszulfátot tartalmazó, krónikus progresszív érbetegségek kezelésére alkalmas gyógyszerkészítmények
WO2002009637A3 (en) Pharmaceutical compositions for the treatment of mucositis, stomatitis and behcet's syndrome
BG101118A (en) Therapeutical compounds
BRPI9908182B8 (pt) composições de proteína de matriz para cura de feridas
DE69731610D1 (de) Orale verabreichung wirksamer mengen von hyaluronsäure
BR0013540A (pt) Formulações farmacêuticas e seu uso na prevenção de acidente vascular cerebral, diabetes e/ou falha de coração congestiva
DE69920757D1 (de) Immunsuppressive wirkungen von pteridinderivaten
ATE452640T1 (de) Mittel für erkrankungen assoziert mit knochensubstanzverlust
AU1865100A (en) Hyaluronate lyase used for promoting penetration in topical agents
HUP9801241A2 (hu) Vastagbélbe beadható, azathioprine tartalmú készítmények és eljárás előállításukra
CA2433833A1 (en) Use of flumazenil in developing a drug for the treatment of alcohol dependence
EA199800717A1 (ru) Способ лечения заболеваний млекопитающих и цвиттерионная композиция
CA2340734A1 (en) Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases
WO2003018535A3 (en) Novel aminobenzoephenones
HUP0003256A2 (hu) Pentozán-poliszulfát és sói alkalmazása krónikus progresszív érhegesedéssel járó betegségek kezelésére alkalmas gyógyszerkészítmények előállítására
WO2003007876A3 (en) N-fatty acid-amino acid conjugates and therapeutic uses
HUP9901659A2 (hu) Flupirtin alkalmazása a hematopoetikus sejtrendszer károsodásával kapcsolatos megbetegedések megelőzésére és gyógyítására alkalmas gyógyszerkészítmény előállítására
CA2429793A1 (en) Interferon therapeutic effect enhancer
WO2000016786A3 (en) Oxihumic acid and its use in the treatment of various conditions
PT1231908E (pt) Composicao farmaceutica compreendendo um composto dador de no e sua utilizacao em terapia

Legal Events

Date Code Title Description
HC9A Change of name, address

Owner name: THE UNITED STATES OF AMERICA, AS REPRESENTED B, US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US

Owner name: IVAX RESEARCH, INC., US

Free format text: FORMER OWNER(S): BAKER NORTON PHARMACEUTICALS, INC., US

FD9A Lapse of provisional protection due to non-payment of fees